Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

Elise A. Chong, MD, Emeline R. Chong, Daniel J. Landsburg, MD, James N. Gerson, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Stefan K. Barta, MDMRCP,MS, Alfred L. Garfall, MD, Elizabeth Weber, BSN, RN, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143348

Published: 2020

Journal Articles

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Natalie F. Uy, MD, Edward Pequignot, Noelle V. Frey, MD, Megan Davis, PhD, Elizabeth O. Hexner, MD, Stephen J. Schuster, MD, Saar Gill, MD PhD, Alison W. Loren, MD, Stephan A Grupp, MD PhD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Joan Gilmore, BS, Lester Lledo, RN,NP, Wei-Ting Hwang, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Carl H June, MD, David L. Porter, MD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-141224

Published: 2020

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Elise A. Chong, MD, James N. Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, David L. Porter, MD, Karen Dengel, BSN, RN, Don L. Siegel, MD PhD, Joan Gilmore, BS, Stefan K. Barta, MD MRCP, MS, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 594.

https://doi.org/10.1182/blood-2019-131078

Published: 2019

Journal Articles

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

Sunita Dwivedy Nasta, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Elise A. Chong, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Daniel J. Landsburg, MD, Meredith I LaRose, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Marco Ruella, MD, Noelle V. Frey, MD, Stephen J. Schuster, MD, David L. Porter, MD

Blood (2019) 134 (Supplement_1): 3240.

https://doi.org/10.1182/blood-2019-130650

Published: 2019

Journal Articles

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Sunita Dwivedy Nasta, MD, Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Daniel J. Landsburg, MD, Elise A. Chong, MD, Stefan K. Barta, MD MRCP, MS, Noelle V. Frey, MD, James N. Gerson, MD, Amit Maity, MD PhD, John Plastaras, MD, David L. Porter, MD, Marco Ruella, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 4108.

https://doi.org/10.1182/blood-2019-131399

Published: 2019

Journal Articles

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Shannon R. McCurdy, MD, Shannon H. Gier, BS, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Alexander E. Perl, MD, Ivan Maillard, MD PhD, Keith W. Pratz, MD, David L. Porter, MD, Martin P. Carroll, MD, Phyllis A. Gimotty, PhD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 2209.

https://doi.org/10.1182/blood-2019-124468

Published: 2019

Journal Articles

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, MD, Chase Walling, BS, Loretta J. Nastoupil, MD MSc, Martina Pennisi, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, MPH, Veronika Bachanova, MD PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Miguel-Angel Perales, MD, Michael R. Bishop, MD, David L. Porter, MD

Blood (2019) 134 (Supplement_1): 1599.

https://doi.org/10.1182/blood-2019-127490

Published: 2019

Journal Articles

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Elise A. Chong, MD, Meredith I LaRose, MD, Steven M. Bair, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elizabeth Weber, BSN, RN, Chase Walling, BS, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 1606.

https://doi.org/10.1182/blood-2019-131482

Published: 2019

Journal Articles

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

Christopher L Nobles, PhD, John K Everett, Shantan Reddy, Joseph A Fraietta, PhD, David L. Porter, MD, Noelle V. Frey, MD, Stephan A. Grupp, MD PhD, Don L. Siegel, MD PhD, Simon F Lacey, PhD BS, Carl H June, MD, Frederic D Bushman, PhD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 4548.

https://doi.org/10.1182/blood-2018-99-117034

Published: 2018

Journal Articles

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

J. Joseph Melenhorst, PhD, David L. Porter, MD, Lifeng Tian, PhD, Simon F Lacey, PhD BS, Christopher L Nobles, PhD, Joseph A Fraietta, PhD, Noelle V. Frey, MD, Irina Kulikovskaya, Minnal Gupta, Regina M Young, PhD, David E Ambrose, BS, Don L. Siegel, MD PhD, Frederic D Bushman, PhD, Carl H June, MD

Blood (2018) 132 (Supplement 1): 699.

https://doi.org/10.1182/blood-2018-99-117390

Published: 2018

Journal Articles

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Mitchell E. Hughes, PharmD, Tracy M. Krause, PharmD, Colleen Timlin, PharmD, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4023.

https://doi.org/10.1182/blood-2018-99-112604

Published: 2018

Journal Articles

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Blood (2018) 132 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2018-99-112944

Published: 2018

Journal Articles

Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8 + T Cells and Impede CAR T Cell Efficacy

Jaco A. C. Van Bruggen, MSc, Anne W. J. Martens, MSc, Joseph A Fraietta, PhD, Tom Hofland, MSc, Sanne Tonino, MD PhD, Eric Eldering, PhD, Mark-David Levin, MDPhD, Peter J. Siska, MD, Sanne Endstra, Jeffrey C Rathmell, PhD, Carl H June, MD, David L. Porter, MD, J. Joseph Melenhorst, PhD, Gerritje J. W. van der Windt, PhD, Arnon P. Kater, MD

Blood (2018) 132 (Supplement 1): 235.

https://doi.org/10.1182/blood-2018-99-115911

Published: 2018

Journal Articles

Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents

Gee Youn (Geeny) Kim, PharmD, Jonathan Burns, PharmD, Craig W. Freyer, PharmD, Keith Hamilton, MD, Mindy Schuster, MD MSCE, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD, Alison W. Loren, MD MS

Blood (2018) 132 (Supplement 1): 5512.

https://doi.org/10.1182/blood-2018-99-119168

Published: 2018

Journal Articles

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Amanda M. Li, MD, George E Hucks, Amanda M. Dinofia, MD, Alix E. Seif, MD, David T Teachey, MD, Diane Baniewicz, Colleen Callahan, Christina Fasano, Beth McBride, Vanessa Gonzalez, Farzana Nazimuddin, MS, David L. Porter, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephan A. Grupp, MD PhD, Shannon L. Maude, MD PhD

Blood (2018) 132 (Supplement 1): 556.

https://doi.org/10.1182/blood-2018-99-112572

Published: 2018

Journal Articles

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Colleen Timlin, PharmD, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, Selina Luger, MD, Jacqueline Smith, MSN, CRNP, Edward Stadtmauer, David L. Porter, MD

Blood (2018) 132 (Supplement 1): 5696.

https://doi.org/10.1182/blood-2018-99-111550

Published: 2018

Journal Articles

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Blood (2018) 132 (Supplement 1): 298.

https://doi.org/10.1182/blood-2018-99-115418

Published: 2018

Journal Articles

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Benjamin M Manning, MD PhD, Robyn T Sussman, PhD, Safoora Deihimi, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, Selina Luger, MD, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Jennifer J.D. Morrissette, PhD, Alexander E. Perl, MD, Edward A. Stadtmauer, MD FACP, David L. Porter, MD, Saar I. Gill, MD PhD

Blood (2018) 132 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2018-99-117410

Published: 2018

Journal Articles

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Elise A. Chong, MD, Bruce L Levine, PhD, Stephan A. Grupp, MD PhD, Megan Davis, PhD, Don L. Siegel, MD PhD, Shannon L. Maude, MD PhD, Whitney Lynn Gladney, PhD, Noelle V. Frey, MD, David L. Porter, MD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 197.

https://doi.org/10.1182/blood-2018-197

Published: 2018

NARROW

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8 + T Cells and Impede CAR T Cell Efficacy

Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only